title: Growth inhibition of transforming growth factor beta on human gastric carcinoma cells: receptor and postreceptor signaling.
abstract: The effect of transforming growth factor beta (TGF-beta) on human gastric carcinoma cell lines was examined. Cell growth and DNA synthesis of TMK-1 were inhibited by TGF-beta, whereas MKN-28 presented no response to TGF-beta. Scatchard plot analysis of TGF-beta binding showed that TMK-1 had a relatively small number of high-affinity receptors, whereas MKN-28 had a large number of low-affinity receptors. By affinity labeling, only the type I receptor (Mr 65,000) for TGF-beta was detected in TMK-1, while three types of receptors, type I, type II (Mr 85,000-95,000), and type III (Mr 250,000-350,000), for TGF-beta were present in MKN-28. TGF-beta treatment reduced p34cdc-2 kinase activity and the level of phosphorylation of retinoblastoma protein in TMK-1, whereas it did not affect them in MKN-28. mRNAs for MYC and platelet-derived growth factor B chain were increased by treatment of TGF-beta on TMK-1. cAMP-responsive element binding activity was decreased by TGF-beta treatment in MKN-28 but not in TMK-1. This was closely correlated with protein kinase C activity. These results suggest that the type I receptor for TGF-beta in human gastric carcinoma cells may be mainly linked with the growth inhibition of TGF-beta by a decrease in retinoblastoma protein phosphorylation by p34cdc-2 without suppression of MYC expression. Conversely, TGF-beta may reduce protein kinase C activity and cAMP-responsive element binding activity in TGF-beta-resistant gastric carcinoma cells.
authors.affiliation: First Department of Pathology, Hiroshima University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Ito
authors.forename: W
authors.initials: W
authors.lastname: Yasui
authors.forename: E
authors.initials: E
authors.lastname: Kyo
authors.forename: H
authors.initials: H
authors.lastname: Yokozaki
authors.forename: H
authors.initials: H
authors.lastname: Nakayama
authors.forename: H
authors.initials: H
authors.lastname: Ito
authors.forename: E
authors.initials: E
authors.lastname: Tahara
mesh_terms: D016203:CDC2 Protein Kinase / Q000378:metabolism; D002277:Carcinoma / Q000473:pathology*; D015870:Gene Expression; D006131:Growth Inhibitors; D006801:Humans; D066298:In Vitro Techniques; D010750:Phosphoproteins / Q000378:metabolism; D010766:Phosphorylation; D010982:Platelet-Derived Growth Factor / Q000235:genetics; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D012334:RNA, Neoplasm / Q000235:genetics; D011956:Receptors, Cell Surface / Q000502:physiology*; D018125:Receptors, Transforming Growth Factor beta; D016160:Retinoblastoma Protein / Q000378:metabolism; D015398:Signal Transduction; D013274:Stomach Neoplasms / Q000473:pathology*; D016212:Transforming Growth Factor beta / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D006131:Growth Inhibitors; D010750:Phosphoproteins; D010982:Platelet-Derived Growth Factor; D016271:Proto-Oncogene Proteins c-myc; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011956:Receptors, Cell Surface; D018125:Receptors, Transforming Growth Factor beta; D016160:Retinoblastoma Protein; D016212:Transforming Growth Factor beta; D016203:CDC2 Protein Kinase